The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
The anaphase promoting complex is required for memory function in micePreprint
Kuczera, T., Stilling, R. M., Hsia, H., Bahari‐Javan, S., Irniger, S., Nasmyth, K., Sananbenesi, F., & Fischer, A. (2010) · Learning & Memory · doi:10.1101/lm.1998411 · Cited by 51
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Effects of d ‐Cycloserine on Extinction and Reconditioning of Ethanol‐Seeking Behavior in Mice
Groblewski, P. A., Lattal, K. M., & Cunningham, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00895.x · Cited by 52
A Meta-Analysis of d-Cycloserine in Exposure-Based Treatment
Mcguire, J. F., Wu, M. S., Piacentini, J. C., McCracken, J. T., & Storch, E. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10334 · Cited by 52
In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation
Davis, M. T., Hillmer, A. T., Holmes, S. E., Pietrzak, R. H., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Carson, R. E., Krystal, J. H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818871116 · Cited by 50
Self-citationAkirav, I., Segev, A., Motanis, H., & Maroun, M. (2009) · Learning & Memory · doi:10.1101/lm.1565109 · Cited by 51
Ershow, A. G., Peterson, C. M., Riley, W. T., Rizzo, A., & Wansink, B. C. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500202 · Cited by 50
Cognitive-behavioral therapy for social anxiety disorder: the state of the science
Gordon, D., Wong, J., & Heimberg, R. G. (2014) · The Wiley Blackwell Handbook of Social Anxiety Disorder · doi:10.1002/9781118653920.ch22 · Cited by 50
Normas brasileiras para o Affective Norms for English Words
Kristensen, C. H., Gomes, C. F. A., Justo, A. R., & Vieira, K. (2011) · Trends in Psychiatry and Psychotherapy · doi:10.1590/s2237-60892011000300003 · Cited by 50
d-Cycloserine enhances durability of social skills training in autism spectrum disorder
Wink, L. K., Minshawi, N. F., Shaffer, R. C., Plawecki, M. H., Posey, D. J., Horn, P. S., Adams, R. E., Pedapati, E. V., Schaefer, T. L., McDougle, C. J., et al. (2017) · Molecular Autism · doi:10.1186/s13229-017-0116-1 · Cited by 51
McNally, G. P., Lee, B.-W., Chiem, J. Y., & Choi, E. A. (2005) · Behavioral Neuroscience · doi:10.1037/0735-7044.119.4.1023 · Cited by 50
Vagus nerve stimulation as a tool for enhancing extinction in exposure-based therapies
Noble, L. J., de Souza, R. R., & McIntyre, C. K. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4994-5 · Cited by 48
de Souza, R. R., Robertson, N. M., Pruitt, D. T., Gonzales, P. A., Hays, S. A., Rennaker, R. L., Kilgard, M. P., & McIntyre, C. K. (2019) · Stress · doi:10.1080/10253890.2019.1602604 · Cited by 49
The effects of yohimbine and amphetamine on fear expression and extinction in rats
Mueller, D. T., Olivera-Figueroa, L. A., Pine, D. S., & Quirk, G. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1491-x · Cited by 49
Golden, G. J., & Houpt, T. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.02.004 · Cited by 49
Haaker, J., Lonsdorf, T. B., & Kalisch, R. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.016 · Cited by 47
Glutamate and anxiety disorders
Amiel, J. M., & Mathew, S. J. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0033-7 · Cited by 50
Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia
Swerdlow, N. R. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.195 · Cited by 47
Pharmacological Enhancement of Behavioral Therapy: Focus on Posttraumatic Stress Disorder
Choi, D. C., ROTHBAUM, B. O., Gerardi, M. A., & Ressler, K. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_10 · Cited by 47
Self-citationRefinement of diagnosis and disease classification in psychiatry
Lecrubier, Y. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-1003-0 · Cited by 47
Park, J. M., Small, B. J., GELLER, D. A., Murphy, T. K., Lewin, A. B., & Storch, E. A. (2013) · Journal of Child and Family Studies · doi:10.1007/s10826-013-9742-1 · Cited by 49
Stress modulation of cognitive and affective processes
Campeau, S., Liberzon, I., Morilak, D. A., & Ressler, K. J. (2011) · Stress · doi:10.3109/10253890.2011.596864 · Cited by 50
Self-citationRich, M. T., Abbott, T. B., Chung, L., Gulcicek, E. E., Stone, K. L., Colangelo, C. M., Lam, T. T., Nairn, A. C., Taylor, J. R., & Torregrossa, M. M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1108-16.2016 · Cited by 47
Sild, M., Ruthazer, E. S., & Booij, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.014 · Cited by 47
Shipherd, J. C., & Salters‐Pedneault, K. (2008) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2008.01.003 · Cited by 48
D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach
MacKillop, J., Few, L. R., Stojek, M. M., Murphy, C. M., Malutinok, S. F., Johnson, F. T., Hofmann, S. G., McGeary, J. E., Swift, R. M., & Monti, P. M. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.41 · Cited by 46
Evidence-Based Assessment and Treatment of Specific Phobias in Adults
Hood, H. K., & Antony, M. M. (2012) · Autism and child psychopathology series · doi:10.1007/978-1-4614-3253-1_2 · Cited by 49
Extinction: Behavioral Mechanisms and Their Implications
Bouton, M. E., & Woods, A. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00088-7 · Cited by 46
Ursano, R. J., Zhang, L., He, L., Johnson, L. R., Carlton, J. R., Fullerton, C. S., & Benedek, D. M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.030 · Cited by 48
Progress in Cue Exposure Therapy for the Treatment of Addictive Disorders: A Review Update
Martin, T., LaRowe, S. D., & Malcolm, R. J. (2013) · The Open Addiction Journal · doi:10.2174/1874941001003010092 · Cited by 46
Ma, L., Mor, S., Anderson, P. L., Baños, R., Botella, C., Bouchard, S., Cárdenas‐López, G., Donker, T., Fernández‐Álvarez, J., Lindner, P., et al. (2021) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2021.1939410 · Cited by 49
Self-citationVirtual Reality Applications to Address the Wounds of War
Rizzo, A., Buckwalter, J. G., Forbell, E., Reist, C., Difede, J., ROTHBAUM, B. O., Lange, B. S., Koenig, S. T., & Talbot, T. B. (2013) · Psychiatric Annals · doi:10.3928/00485713-20130306-08 · Cited by 45
Self-citationNave, A. M., Tolin, D., & Stevens, M. (2012) · Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07564 · Cited by 48
Addiction: the clinical interface
Nutt, D., & Lingford-Hughes, A. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.101 · Cited by 46
Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders
Pull, C. B. (2006) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3280115e52 · Cited by 46
Psychosocial Approaches of Acute Stress Reactions
Bryant, R. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900019453 · Cited by 45
Marenco, S., & Weinberger, D. R. (2006) · CNS Drugs · doi:10.2165/00023210-200620030-00001 · Cited by 45
Inslicht, S. S., Niles, A. N., Metzler, T. J., Lipshitz, S. L., Otte, C., Milad, M. R., Orr, S. P., Marmar, C. R., & Neylan, T. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01222-z · Cited by 44
Acheson, D. T., Feifel, D., Kamenski, M., Mckinney, R., & Risbrough, V. B. (2015) · Depression and Anxiety · doi:10.1002/da.22362 · Cited by 44
Fibroblast Growth Factor-2 Enhances Extinction and Reduces Renewal of Conditioned Fear
Graham, B. M., & Richardson, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.3 · Cited by 44
Friedman, M. J. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780195399066.013.0036 · Cited by 45
Targeted treatments in autism and fragile X syndrome
Gürkan, C. K., & Hagerman, R. J. (2012) · Research in Autism · doi:10.1016/j.rasd.2012.05.007 · Cited by 45
Advances in pharmacotherapy for pediatric anxiety disorders
Rynn, M. A., Puliafico, A. C., Heleniak, C. M., Rikhi, P., Ghalib, K., & Vidair, H. B. (2011) · Depression and Anxiety · doi:10.1002/da.20769 · Cited by 45
Effects of D-Cycloserine on Extinction: Consequences of Prior Exposure to Imipramine
Werner-Seidler, A., & Richardson, R. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.010 · Cited by 43
Graham, B. M., Callaghan, B. L., & Richardson, R. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.07.012 · Cited by 49
Storsve, A. B., McNally, G. P., & Richardson, R. (2010) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.12.011 · Cited by 43
Neuroscience of learning and memory for addiction medicine
Torregrossa, M. M., & Taylor, J. R. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.006 · Cited by 43
Facilitation of Extinction of Conditioned Fear by D-Cycloserine: Implications for Psychotherapy
Davis, M., Myers, K. M., Ressler, K. J., & Rothbaum, B. O. (2005) · Current Directions in Psychological Science · doi:10.1111/j.0963-7214.2005.00367.x · Cited by 43
Self-citationVirtual reality applications for exposure
Bouchard, S., Côté, S., & Richard, D. C. S. (2007) · Elsevier eBooks · doi:10.1016/b978-012587421-2/50017-x · Cited by 46
Erlich, J. C., Bush, D. E. A., & LeDoux, J. E. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00016 · Cited by 40
Delay aversion: Effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and d-cycloserine
van den Bergh, F. S., Bloemarts, E., Groenink, L., Olivier, B., & Oosting, R. S. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.007 · Cited by 42
Development and Clinical Results from the Virtual Iraq Exposure Therapy Application for PTSD
Rizzo, A., Newman, B., Parsons, T. D., Reger, G. M., Holloway, K. M., Gahm, G., Rothbaum, B. O., Difede, J., McLay, R. N., Johnston, S. L., et al. (2009) · International Conference on Virtual Rehabilitation · doi:10.1109/icvr.2009.5174198 · Cited by 42
Self-citationClinical Results Using Virtual Reality
Rizzo, A., Koenig, S. T., & Talbot, T. B. (2019) · Journal of Technology in Human Services · doi:10.1080/15228835.2019.1604292 · Cited by 47
Akirav, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301050 · Cited by 41
Davis, A. R., Shields, A. D., Brigman, J. L., Norcross, M. A., McElligott, Z. A., Holmes, A., & Winder, D. G. (2008) · Learning & Memory · doi:10.1101/lm.1079308 · Cited by 42
Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
Differential roles of mGlu7 and mGlu8 in amygdala-dependent behavior and physiology
Fendt, M., Imobersteg, S., Peterlik, D., Chaperon, F., Mattes, C., Wittmann, C., Olpe, H.-R., Mosbacher, J., Vranesic, I., van der Putten, H., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.052 · Cited by 40
Histone-acetylation: a link between Alzheimer's disease and post-traumatic stress disorder?
Bahari‐Javan, S., Sananbenesi, F., & Fischer, A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00160 · Cited by 40
Galantamine improves sustained attention in chronic cocaine users.
Sofuoglu, M., Waters, A. J., Poling, J. C., & Carroll, K. M. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0022213 · Cited by 41
Zwanzger, P., Zavorotnyy, M., Gencheva, E., Diemer, J., Kugel, H., Heindel, W. L., Ruland, T., Ohrmann, P., Arolt, V., Domschke, K., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.61 · Cited by 41
d-Cycloserine Facilitates Extinction of Cocaine Self-Administration in Rats
Thanos, P. K., Bermeo, C., Wang, G.-J., & Volkow, N. D. (2011) · Synapse · doi:10.1002/syn.20922 · Cited by 46
Asnaani, A., McLean, C. P., & Foa, E. B. (2016) · Behavior Therapy · doi:10.1016/j.beth.2016.02.003 · Cited by 41
Peskin, M., Wyka, K., Cukor, J., Olden, M., Altemus, M., Lee, F. S., & Difede, J. (2019) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2018.03.001 · Cited by 40
NMDA receptor modulators: an updated patent review (2013 – 2014)
Strong, K. L., Jing, Y., Prosser, A. R., Traynelis, S. F., & Liotta, D. C. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.972938 · Cited by 43
Extinction retention predicts improvement in social anxiety symptoms following exposure therapy
Berry, A. C., Rosenfield, D., & Smits, J. A. J. (2008) · Depression and Anxiety · doi:10.1002/da.20511 · Cited by 40
GOFF, D. C. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160225154812 · Cited by 40
Clinical Virtual Reality: Emerging Opportunities for Psychiatry
Rizzo, A., Koenig, S. T., & Talbot, T. B. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180011 · Cited by 45
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
Graham, B. M., & Richardson, R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.14 · Cited by 40
Translational research perspectives on maximizing the effectiveness of exposure therapy
Powers, M. B., Smits, J. A. J., Leyro, T. M., & Otto, M. W. (2007) · Elsevier eBooks · doi:10.1016/b978-012587421-2/50005-3 · Cited by 40
Kamboj, S. K., Massey-Chase, R. A., Rodney, L., Das, R., Almahdi, B., Curran, H. V., & Morgan, C. J. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2254-z · Cited by 39
Early postnatal stress alters the extinction of context-dependent conditioned fear in adult rats.
Matsumoto, M., Togashi, H., Konno, K., Koseki, H., Hirata, R., Izumi, T., Yamaguchi, T., & Yoshioka, M. (2008) · Pharmacology, Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.017 · Cited by 43
From antipsychotic to anti-schizophrenia drugs: role of animal models
Geyer, M. A., Olivier, B., Joëls, M., & Kahn, R. S. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.06.006 · Cited by 40
Genetic Approaches to Modeling Anxiety in Animals
Jacobson, L. H., & Cryan, J. F. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_31 · Cited by 40
Sandberg, A. (2011) · Wiley eBooks · doi:10.1002/9781444393552.ch5 · Cited by 40
Peripheral effects of vagus nerve stimulation on anxiety and extinction of conditioned fear in ratsPreprint
Noble, L. J., Chuah, A., Callahan, K. K., de Souza, R. R., & McIntyre, C. K. (2019) · Learning & Memory · doi:10.1101/lm.048447.118 · Cited by 40
Brenhouse, H. C., Dumais, K., & Andersen, S. L. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.063 · Cited by 38
Toth, I., Dietz, M., Peterlik, D., Huber, S. E., Fendt, M., Neumann, I. D., Flor, P. J., & Slattery, D. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.021 · Cited by 39
Serine Racemase and D-serine in the Amygdala Are Dynamically Involved in Fear Learning
Balu, D. T., Presti, K. T., Huang, C. C., Muszynski, K., Radzishevsky, I. S., Wolosker, H., Guffanti, G., Ressler, K. J., & Coyle, J. T. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.012 · Cited by 38
Self-citationDaubner, J., Arshaad, M. I., Henseler, C., Hescheler, J., Ehninger, D., Broich, K., Rawashdeh, O., Papazoglou, A., & Weiergräber, M. (2021) · Neural Plasticity · doi:10.1155/2021/8823383 · Cited by 44
Love and Fear of Heights: The Pathophysiology and Psychology of Height Imbalance
Salassa, J. R., & Zapala, D. A. (2009) · Wilderness and Environmental Medicine · doi:10.1580/1080-6032-020.004.0378 · Cited by 38
Treatment of Obsessive-Compulsive Disorder
Stein, D. J., Ipser, J., Baldwin, D. S., & Bandelow, B. (2007) · CNS Spectrums · doi:10.1017/s1092852900002480 · Cited by 38
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 41
Associative Learning and Conditioning Theory
Laborda, M. A., McConnell, B. L., & Miller, R. R. (2011) · Cited by 36
Reversing Behavioral, Neuroanatomical, and Germline Influences of Intergenerational Stress
Aoued, H. S., Sannigrahi, S., Doshi, N. K., Morrison, F. G., Linsenbaum, H., Hunter, S. C., Walum, H., Baman, J., Yao, B., Jin, P., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.028 · Cited by 38
Self-citationd-Cycloserine and performance under different states of anxiety in healthy volunteers
Bailey, J., Papadopoulos, A., Lingford-Hughes, A. R., & Nutt, D. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0817-9 · Cited by 37
Kuriyama, K., Honma, M., Yoshiike, T., & Kim, Y. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.045 · Cited by 36
Virtual reality interventions for the treatment of anxiety disorders: A scoping review
Andersen, N. J., Schwartzman, D., Martinez, C., Cormier, G., & Drapeau, M. (2023) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2023.101851 · Cited by 37
Sharp, W. G., Allen, A. G., Stubbs, K. H., Criado, K. K., Sanders, R., McCracken, C. E., Parsons, R. G., Scahill, L. D., & Gourley, S. L. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.126 · Cited by 39
Swerdlow, N. R., Bhakta, S. G., & Light, G. A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.037 · Cited by 36
Effects of D-Cycloserine Administration on Weekly Nonemotional Memory Tasks in Healthy Participants
Otto, M. W., Basden, S. L., McHugh, R. K., Kantak, K. M., Deckersbach, T., Cather, C., GOFF, D. C., Hofmann, S. G., Berry, A. C., & Smits, J. A. J. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000172620 · Cited by 37
Glucocorticoid augmentation of prolonged exposure therapy: rationale and case report
Yehuda, R., Bierer, L. M., Pratchett, L. C., & Malowney, M. (2010) · European Journal of Psychotraumatology · doi:10.3402/ejpt.v1i0.5643 · Cited by 36
Conditioned stimulus familiarity determines effects of MK-801 on fear extinction.
Chan, W. Y. M., & McNally, G. P. (2009) · Behavioral Neuroscience · doi:10.1037/a0014988 · Cited by 36
Limitations of Pharmacotherapy: Behavioral Approaches to Chronic Pain
Flor, H., & Diers, M. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_15 · Cited by 36
Handford, C., Tan, S., Lawrence, A., & Kim, J. (2014) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000303 · Cited by 33
Improper activation of D1 and D2 receptors leads to excess noise in prefrontal cortex
Avery, M. C., & Krichmar, J. L. (2015) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2015.00031 · Cited by 37
Simón, D., Kischkel, E., Spielberg, R., & Kathmann, N. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.12.022 · Cited by 35
d-Cycloserine enhances conditioned taste aversion learning in rats
Nunnink, M., Davenport, R. A., Ortega, B., & Houpt, T. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.006 · Cited by 35
Torregrossa, M. M., Gordon, J., & Taylor, J. R. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0489-13.2013 · Cited by 35
A systematic review and meta‐analysis of treatments for acrophobia
Arroll, B., Wallace, H. B., Mount, V., Humm, S. P., & Kingsford, D. W. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.00540 · Cited by 35
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
